New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:58 EDTSLXPSalix Xifaxan data paves way for approval, says Sterne Agee
After Salix's Xifaxan drug met its primary endpoint in a study, Sterne Agee thinks the data should enable the drug to be approved as a treatment for IBS-D. The firm believes that the stock could reach $180 and it keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SLXP

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use